NCT01450280View on ClinicalTrials.gov

Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63 CS

ChAd63 CS 5x10\^9 vp intra-muscularly Day 0

BIOLOGICAL

ChAd63 CS, MVA CS

ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56

BIOLOGICAL

ChAd63 CS

ChAd63 CS 5x10\^10 vp intra-muscularly Day 0

BIOLOGICAL

ChAd63, MVA CS

ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56

Trial Locations (1)

Unknown

Clinical Research Centre Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital, Dublin

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01450280 - Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS | Biotech Hunter | Biotech Hunter